Fair Value Calculator Fair Value Calculator
EN DE

DaBomb Protein Biotech Corp (6578) Fair Value & Analysis

Consumer Defensive · TW · Market cap 1.2B TWD

DP DaBomb Protein Biotech Corp 6578 · TWO
Price16.45 TWD
Fair Value1.79 TWD
Upside-89.1%
Quality33/100
Watch DaBomb Protein Biotech Corp for free — get notified when fair value or trend changes. Watch for free
Evidence: Low Range 1.21 TWD – 2.37 TWD

Fair value as of: Jul 12, 2026

From 2 valuation models · updated today

Fair value updated Jul 12, 2026 — revised from 75.63 TWD to 1.79 TWD (−97.6%) since Jun 24, 2026. Share price −0.9% over the past month.

Price vs Fair Value (12 months)

25.55 TWD 14.65 TWD Fair Value 1.79 TWD Jun 2025 Jul 2026

12‑month range 14.65 TWD – 25.55 TWD · fair‑value band 1.21 TWD – 2.37 TWD · the 16.45 TWD price screens above the 1.79 TWD fair value. As of Jul 12, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

DaBomb Protein Biotech Corp (6578) currently trades at 16.45 TWD, while our model-based Fair Value estimate is 1.79 TWD — implying the stock looks roughly 89.1% overvalued today. We read business quality at 33/100 (below-average quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Over the trailing twelve months, DaBomb Protein Biotech Corp generated revenue of 323M TWD at a net margin of -20.4%. Revenue grew 19.7% year over year. It earns a return on equity of -6.3%. Net debt stands at 38.0M TWD. Fundamentals as of Jul 12, 2026

Our scenario range runs from 1.21 TWD (bear case) to 2.37 TWD (bull case); at 16.45 TWD, the current price sits above that range. The share trades about 37% below its 52-week high and 15% above its 52-week low, currently below its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at -27% fair-value upside — at -89%, 6578 screens richer than that median.

Key figures & financial health

Revenue (TTM) 323M TWD
Revenue growth (YoY) +19.7%
Net margin -20.4%
Return on equity -6.3%
Free cash flow −21.0M TWD FY2025
Operating margin 0.9%
More key figures
EPS (TTM) -0.9600 TWD
EPS growth (YoY) +164%
Net debt 38.0M TWD FY2023

Figures from reported company fundamentals (EODHD) · as of Jul 12, 2026. TTM = trailing twelve months.

About the company

DaBomb Protein Biotech Corp. manufactures and sells hydrolyzed soy protein in Vietnam, the Philippines, South Korea, Taiwan, and Asia. It offers nutrition and health care for aquatic products and economic animals; and pet health care products. The company also offers contract development and manufacturing organization services, including research and development, process design, and mass production services; product packaging solutions; and product formulation design and customized development services. It serves pet health food brands, pet nutrition product distribution channels, livestock feed enterprises, animal nutrition brands, and aquaculture industries. The company was formerly known as DaBomb Protein Corp. and changed its name to DaBomb Protein Biotech Corp. in October 2023. DaBomb Protein Biotech Corp. was incorporated in 2001 and is based in Tainan City, Taiwan.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

DaBomb Protein Biotech Corp reported revenue of 309M TWD in FY2025 versus 471M TWD in FY2021, a compound −10.0%/yr. Reported net income was −69.3M TWD in FY2025.

Revenue −10.0%/yr
FY21 471M TWD
FY22 434M TWD
FY23 384M TWD
FY24 338M TWD
FY25 309M TWD
Net income
FY21 −62.4M TWD
FY22 −44.7M TWD
FY23 −57.0M TWD
FY24 11.6M TWD
FY25 −69.3M TWD

Is 6578 fairly valued? → Check now

🧮 Run the numbers yourself — free valuation calculators
📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog — it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "DaBomb Protein Biotech Corp Fair Value". https://www.fairvalue-calculator.com/stock/6578

Similar stocks

10 more Packaged Foods stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).

Stock Price Fair Value vs Fair Value
Nestlé S.A NSRGF $97.58 $65.41 -33%
Nestlé India Limited NESTLEIND ₹1,438 ₹362.37 -75%
Grupo Bimbo, S.A. BIMBOA 57.10 MXN 83.34 MXN +46%
Uni-President Enterprises Corp 1216 75.60 TWD 55.53 TWD -27%
Britannia Industries Limited BRITANNIA ₹5,218 ₹3,567 -32%
Tata Consumer Products Limited TATACONSUM ₹1,131 ₹339.05 -70%
PT Indofood CBP Sukses Makmur Tbk ICBP 6,600 IDR 14,500 IDR +120%
Samyang Foods Co 003230 1,000,000 KRW 1,066,643 KRW +7%
PT Indofood Sukses Makmur Tbk INDF 6,250 IDR 22,853 IDR +266%
Patanjali Foods Limited PATANJALI ₹420.45 ₹294.68 -30%

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is DaBomb Protein Biotech Corp (6578) undervalued?
As of Jul 12, 2026, our model estimates a fair value of 1.79 TWD versus a price of 16.45 TWD — about −89% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 6578?
Our model-based fair value for DaBomb Protein Biotech Corp is 1.79 TWD (as of Jul 12, 2026), built from audited fundamentals. The current price is 16.45 TWD.
What is the quality score of 6578?
DaBomb Protein Biotech Corp has a Quality Score of 33/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of DaBomb Protein Biotech Corp (6578)?
DaBomb Protein Biotech Corp reported trailing-twelve-month revenue of about 323M TWD (latest available figure, as of Jul 12, 2026).
What is the net profit margin of 6578?
The net profit margin of DaBomb Protein Biotech Corp is about -20.4%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

14 days Pro free · no card

Unlock the full DaBomb Protein Biotech Corp analysis — and try Pro free

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.